The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ALS in the EU.

CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...

First major treatment advance in nearly 25 years; Gliomas target individuals in the prime of life, often in their 30s and 40s ...

Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, ...

Samsung Biologics landed a $1.24 billion contract manufacturing deal with an Asian pharmaceutical giant, shattering its ...

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...

Sanofi said its Opella business has been valued at around 16 billion euros (USD17.38 billion), or 14 times EBITDA in 2024 ...